Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 42.7% in May

Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 5,100 shares, a drop of 42.7% from the April 30th total of 8,900 shares. Based on an average trading volume of 1,400 shares, the short-interest ratio is presently 3.6 days.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Tang Capital Management LLC bought a new position in shares of Molecular Partners in the 3rd quarter worth $105,000. AlphaCentric Advisors LLC acquired a new position in Molecular Partners during the 3rd quarter valued at about $218,000. Federated Hermes Inc. increased its position in Molecular Partners by 94.2% during the 1st quarter. Federated Hermes Inc. now owns 457,037 shares of the company’s stock valued at $9,264,000 after buying an additional 221,743 shares in the last quarter. Susquehanna International Group LLP acquired a new position in Molecular Partners during the 4th quarter valued at about $218,000. Finally, OLD Mission Capital LLC acquired a new position in Molecular Partners during the 4th quarter valued at about $30,000. 2.56% of the stock is owned by institutional investors.

Molecular Partners Price Performance

Shares of MOLN stock opened at $6.55 on Friday. Molecular Partners has a 52-week low of $5.50 and a 52-week high of $8.00. The stock has a 50 day moving average price of $6.37 and a 200 day moving average price of $6.49.

Molecular Partners (NASDAQ:MOLN – Get Rating) last released its quarterly earnings data on Friday, May 12th. The company reported ($0.49) EPS for the quarter. The business had revenue of $3.30 million during the quarter. On average, equities analysts anticipate that Molecular Partners will post -2.05 earnings per share for the current fiscal year.

Molecular Partners Company Profile

(Get Rating)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.